Our results are in line with prior preclinical reports demonstrating that sitagliptin as well as the GLP-1R agonist liraglutide mitigated motor deficits, striatal DA loss, SNc dopaminergic neuronal degeneration and neuroinflammation in a rat rotenone model of PD [75, 76]. Here, GLP1R is linked to Parkinson disease.